NovoCure Management
Management criteria checks 4/4
NovoCure's CEO is Asaf Danziger, appointed in Jan 2002, has a tenure of 22.33 years. total yearly compensation is $1.52M, comprised of 49.7% salary and 50.3% bonuses, including company stock and options. directly owns 0.013% of the company’s shares, worth $318.26K. The average tenure of the management team and the board of directors is 3.7 years and 6.5 years respectively.
Key information
Asaf Danziger
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 49.7% |
| CEO tenure | 22.3yrs |
| CEO ownership | 0.01% |
| Management average tenure | 3.7yrs |
| Board average tenure | 6.5yrs |
Recent management updates
Recent updates
NovoCure Limited Q1 Earnings: Core Business Accelerating
May 03NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?
Apr 08
NovoCure: Sell The METIS-Inspired Rally
Mar 28Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio
Mar 03NovoCure: Stay Cautious Amid Positive Signs
Jan 19Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Nov 16Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?
Aug 13Is NovoCure (NASDAQ:NVCR) A Risky Investment?
May 15A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)
Apr 24Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching
Feb 10Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Jan 16NovoCure: See Past Market Myopia And Buy The Dip
Sep 27Novocure creates new CNS focused franchise to renew growth in brain cancer business
Sep 21Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Sep 09NovoCure: Does The Reward Outweigh The Risk? I Believe So
Sep 09NovoCure Q2 2022 Earnings Preview
Jul 27Is NovoCure (NASDAQ:NVCR) Using Too Much Debt?
May 28NovoCure: A Stalwart With More Upsides
May 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$193m |
| Dec 31 2023 | US$2m | US$756k | -US$207m |
| Sep 30 2023 | n/a | n/a | -US$197m |
| Jun 30 2023 | n/a | n/a | -US$174m |
| Mar 31 2023 | n/a | n/a | -US$141m |
| Dec 31 2022 | US$2m | US$831k | -US$93m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | n/a | n/a | -US$68m |
| Mar 31 2022 | n/a | n/a | -US$59m |
| Dec 31 2021 | US$1m | US$876k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$27m |
| Jun 30 2021 | n/a | n/a | -US$5m |
| Mar 31 2021 | n/a | n/a | US$12m |
| Dec 31 2020 | US$9m | US$782k | US$20m |
| Sep 30 2020 | n/a | n/a | US$19m |
| Jun 30 2020 | n/a | n/a | US$12m |
| Mar 31 2020 | n/a | n/a | US$9m |
| Dec 31 2019 | US$7m | US$702k | -US$7m |
| Sep 30 2019 | n/a | n/a | -US$27m |
| Jun 30 2019 | n/a | n/a | -US$41m |
| Mar 31 2019 | n/a | n/a | -US$55m |
| Dec 31 2018 | US$5m | US$693k | -US$64m |
| Sep 30 2018 | n/a | n/a | -US$59m |
| Jun 30 2018 | n/a | n/a | -US$59m |
| Mar 31 2018 | n/a | n/a | -US$64m |
| Dec 31 2017 | US$4m | US$698k | -US$62m |
Compensation vs Market: Asaf's total compensation ($USD1.52M) is below average for companies of similar size in the US market ($USD6.67M).
Compensation vs Earnings: Asaf's compensation has been consistent with company performance over the past year.
CEO
Asaf Danziger (57 yo)
22.3yrs
Tenure
US$1,521,026
Compensation
Mr. Asaf Danziger is a Director at Airway Therapeutics, Inc. since April 2020. He has been the Chief Executive Officer of Novocure Limited since 2002 and its Director since 2012 respectively and also serve...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 20.3yrs | US$1.43m | 0.51% $ 12.5m | |
| CEO & Director | 22.3yrs | US$1.52m | 0.013% $ 318.3k | |
| Chief Financial Officer | 3.7yrs | US$6.32m | 0.083% $ 2.0m | |
| Chief Operating Officer | 3.7yrs | US$5.97m | 0.17% $ 4.2m | |
| General Counsel | 2.1yrs | US$4.86m | 0.019% $ 457.8k | |
| Executive VP & President of Novocure Oncology | 3.7yrs | US$5.04m | 0.052% $ 1.3m | |
| Founder & CTO | 24.3yrs | US$282.51k | no data | |
| Chief Science Officer | 1.3yrs | no data | 0.0065% $ 159.4k | |
| VP of Investor Relations | no data | no data | no data | |
| Chief Human Resources Officer | less than a year | no data | no data | |
| Chief Innovation Officer | 1.3yrs | no data | 0.058% $ 1.4m | |
| Senior VP | no data | no data | no data |
3.7yrs
Average Tenure
54yo
Average Age
Experienced Management: NVCR's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 20.3yrs | US$1.43m | 0.51% $ 12.5m | |
| CEO & Director | 12.3yrs | US$1.52m | 0.013% $ 318.3k | |
| Independent Director | 5.8yrs | US$446.09k | 0.0024% $ 57.8k | |
| Independent Director | 6yrs | US$426.09k | 0.0085% $ 207.8k | |
| Independent Director | 3.3yrs | US$448.53k | 0.000070% $ 1.7k | |
| Independent Director | 12.6yrs | US$435.53k | 0.070% $ 1.7m | |
| Lead Independent Director | 18.3yrs | US$475.53k | 0.15% $ 3.7m | |
| Independent Director | 7yrs | US$446.09k | 0.015% $ 355.5k | |
| Independent Director | 1.2yrs | US$696.94k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$697.26k | 0% $ 0 |
6.5yrs
Average Tenure
61yo
Average Age
Experienced Board: NVCR's board of directors are considered experienced (6.5 years average tenure).